New Therapies for Hairy Cell Leukemia

doi:10.4172/2329-6917.1000e106 Copyright: © 2014 Robak T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hairy Cell Leukemia (HCL) is a B-cell chronic lymphoproliferative disorder characterized by marked splenomegaly, progressive pancytopenia and reactive marrow fibrosis [1]. The annual incidence of HCL is estimated to be 0.3 cases per 100 000 [2]. Hairy cells characteristically stain strongly positive for tartrate-resistant acid phosphatase, a typical pattern of B-cell antigen expression (CD19, CD20) and coexpression of CD11c, CD25 and CD103. Cell surface markers which are associated with normal B-cell activation, especially CD22, CD25, CD72 and CD40, are strongly expressed by leukemic cells [3]. Recently, the BRAF V600E mutation has been found in all evaluate